← Human Trials & Peer-Reviewed Studies
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
Plain-language guide to PMID 17409317 (2007): double-blind randomized controlled trial study of Angiotensin II in 1428 patients, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 17409317
- Journal
- Journal of the American Society of Nephrology : JASN
- Year
- 2007
- Study type
- Randomized Controlled Trial
- Authors
- Eijkelkamp WB et al. (11 authors)
- DOI
- 10.1681/ASN.2006050445
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin II in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.
However, the current use of renin-angiotensin-system intervention is targeted to BP only.
Investigated were the extent of discordance in treatment effects on systolic BP (SBP) and albuminuria and its association with renal outcome in a multivariate Cox model.
Who Took Part
The study group was 1428 patients.
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.
As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.
What Was Measured
Investigated were the extent of discordance in treatment effects on systolic BP (SBP) and albuminuria and its association with renal outcome in a multivariate Cox model.
Topics PubMed links to this paper include Albuminuria, Angiotensin II, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Hypertension and Losartan.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 1428 patients in people with low blood pressure and orthostatic hypotension.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2007 (Journal of the American Society of Nephrology : JASN), a journal based in United States.
More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.